-
Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD
•
Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its EYP-1901 intravitreal implant, intended for the treatment of wet age-related macular degeneration (wAMD). The drug candidate is a combination of vorolanib, a multi-target tyrosine kinase VEGFR/PDGFR inhibitor, and…
-
EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial
•
EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert; EYP-1901) did not meet its primary endpoints in the Phase II PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR). Although the trial data showed some treatment effect, including a reduction in NPDR progression rates at…
-
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
•
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans to sell 2,910,501 shares of EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT), representing a 5.96% stake in the US company. The transaction is expected to generate proceeds of USD 56.66 million (HKD 443 million). EyePoint Pharmaceuticals, established…
